| scholarly article | Q13442814 |
| P356 | DOI | 10.1093/RHEUMATOLOGY/28.5.410 |
| P698 | PubMed publication ID | 2571386 |
| P2093 | author name string | D R Stanworth | |
| M J Davis | |||
| P T Dawes | |||
| I V Lewin | |||
| E Beswick | |||
| P433 | issue | 5 | |
| P921 | main subject | ankylosing spondylitis | Q52849 |
| P304 | page(s) | 410-413 | |
| P577 | publication date | 1989-10-01 | |
| P1433 | published in | British Journal of Rheumatology | Q27709787 |
| P1476 | title | Sulphasalazine therapy in ankylosing spondylitis: its effect on disease activity, immunoglobulin A and the complex immunoglobulin A-alpha-1-antitrypsin | |
| P478 | volume | 28 |
| Q37534395 | A systematic MEDLINE analysis of therapeutic approaches in ankylosing spondylitis |
| Q67465264 | Ankylosing spondylitis. Current drug treatment |
| Q36495453 | Are there any antirheumatic drugs that modify the course of ankylosing spondylitis? |
| Q77120985 | Current guidelines for the drug treatment of ankylosing spondylitis |
| Q92421812 | Disease Activity and Patient-Reported Health Measures in Relation to Cytokine Levels in Ankylosing Spondylitis |
| Q70867172 | Does methotrexate affect serum level of IgA-alpha-1 antitrypsin complex in early rheumatoid arthritis? |
| Q71836850 | Does the serum level of IgA-alpha-1-antitrypsin complex correlate with radiological progression in early rheumatoid arthritis? A 3-year follow-up study |
| Q35537104 | Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial |
| Q33564950 | Evaluation of sulphasalazine in the treatment of spondyloarthropathies |
| Q33567171 | Evidence for differential effects of sulphasalazine on systemic and mucosal immunity in rheumatoid arthritis |
| Q72011183 | IgA-alpha-1-antitrypsin complex in systemic lupus erythematosus: preliminary report |
| Q33766861 | Increased expression of carbonic anhydrase I in the synovium of patients with ankylosing spondylitis |
| Q35694939 | Interactions of the innate and adaptive arms of the immune system in the pathogenesis of spondyloarthritis |
| Q39389171 | Oral Anaerobic Bacteria in the Etiology of Ankylosing Spondylitis |
| Q38499216 | Periodontal pathogens are likely to be responsible for the development of ankylosing spondylitis |
| Q36286209 | Pharmacological treatment of ankylosing spondylitis: a systematic review |
| Q37879332 | Prognosis, course of disease, and treatment of the spondyloarthropathies |
| Q39230946 | Second-line treatment in seronegative spondylarthropathies |
| Q33564159 | Spondyloarthropathies and IgA deficiency |
| Q24187791 | Sulfasalazine for ankylosing spondylitis |
| Q24244129 | Sulfasalazine for ankylosing spondylitis |
| Q41921185 | Survival of disease-modifying antirheumatic drugs used as the first antirheumatic medication in the treatment of ankylosing spondylitis in Finland. A nationwide population-based register study |
| Q72111948 | [Spondylarthropathies and the IgA system] |
Search more.